Approach to Older Adults with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia
Philadelphia-chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) has historically been associated with poor outcomes in older patients due to adverse disease biology, as well as inferior tolerance of conventional chemotherapy. Fortunately, novel therapies, including inotuzumab ozogamicin, blinatumomab, and venetoclax, are now being incorporated into first-line therapy to improve efficacy and decrease toxicity of initial therapy. Inotuzumab ozogamicin, alone or in combination with low intensity chemotherapy, appears to be best suited for the induction phase of treatment due to efficacy in the setting of high tumor burden.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Shai Shimony, Marlise R. Luskin Tags: Review Article Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biology | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Toxicology